Repligen Corp
RGEN · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Repligen Corp at a glance
In FY2025, Repligen Corp reported revenue of USD 738,256 thousands, EBITDA of USD 120,305 thousands, EBITDA margin of 16.3%.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 634,439 | 738,256 | |||
| EBITDA | 37,750 | 120,305 | |||
| EBITDA margin | 6.0% | 16.3% | |||
| Free cash flow | 149,717 | 93,898 | |||
| ROIC | -2.8% | 3.1% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas